Compare Costco Wholesale Corporation (COST) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Costco Wholesale Corporation vs Smith & Nephew plc — how do they compare? Costco Wholesale Corporation trades at $945.05 (market cap $420.05B), while Smith & Nephew plc trades at $27.21 (market cap $11.10B). The key difference: Costco Wholesale Corporation is far larger — about 37.8× Smith & Nephew plc's market cap, and Smith & Nephew plc pays the higher dividend (2.95%). Which is the better fit depends on your goals — on Pluang, investors hold Costco Wholesale Corporation for 133 Days and Smith & Nephew plc for 121 Days on average.
| COST | SNN | |
|---|---|---|
Market Cap | $420.05B | $11.10B |
Volume | 2,087,565 | 1,051,703 |
Sector | Consumer Staples | Health |
52-Week High | $1.09K | $37.17 |
52-Week Low | $849.63 | $26.42 |
Typical Hold Time | 133 Days | 121 Days |
Enterprise Value | $407.33B | $14.13B |
Dividend Yield | 0.62% | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
COST trades at $946.92, up 0.5% today, near its pivot point of $947. The stock shows a bullish technical trend with strong moving averages, though oscillators indicate overbought conditions. Fundamentally, revenue grew to $275.24B in 2025 with a net income margin of 3.04%, while the P/E ratio of 45.66 reflects a premium valuation. Recent news highlights strong March sales growth of 11.3% year-over-year and a membership fee increase, signaling pricing power.
The outlook remains positive with analyst consensus strongly favoring Buy (66.1%) and a price target of $1,100, implying ~16% upside. Key risks include high valuation sensitivity and competitive pressures. Earnings growth and membership renewal rates are critical catalysts for sustained appreciation, but any miss could trigger a pullback.
Smith+Nephew (SNN) trades at $27.24, near its 52-week low of $27.05, with a bearish technical signal despite recent earnings beats. Revenue grew to $6.16B in 2025, with net income margin improving to 10.08%, but the stock faces headwinds from analyst downgrades and CFO departure news. Product launches like the EVOS PELVIC System highlight innovation, yet investor sentiment remains cautious.
The outlook is mixed: strong fundamentals and undervaluation (P/E 18.34) offer upside, but technical weakness and competitive risks temper near-term gains. Key risks include execution challenges and market volatility, while institutional interest (e.g., BlackRock's $505M stake) provides support. Investors should weigh solid profitability against sentiment-driven price pressure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Costco Wholesale Corporation
The leading warehouse club, Costco has 815 stores worldwide (at the end of fiscal 2021), with most sales derived in the United States (72%) and Canada (14%). It sells memberships that allow customers to shop in its warehouses, which feature low prices on a limited product assortment. Costco mainly caters to individual shoppers, but roughly 20% of paid members carry business memberships. Food and sundries accounted for 40% of fiscal 2021 sales, with non-food merchandise 29%, warehouse ancillary and other businesses (such as fuel and pharmacy) nearly 17%, and fresh food 14%. Costco's warehouses average around 146,000 square feet
Read more on COST →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
